EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro activity and in vivo efficacy of sulopenem against Bacillus anthracis in inhalational anthrax mouse and rabbit models

Jennifer Chua iD, Annette M Gray, Steven I Aronin iD, Sailaja Puttagunta, Michael W Dunne iD, Stephanie A Halasohoris, Jade L Spencer, Ashley L Babyak, Majorie E Torres, Bobby J Curry, Christopher P Klimko, Christopher K Cote iD und 2 weitere

Antimicrobial Agents and Chemotherapy · 05.08.2026 · 70 (8)

DOI: 10.1128/aac.00399-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.08.2026. Verfasst von Jennifer Chua und 13 weiteren Autor:innen. Beteiligte Einrichtung: Bacteriology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA. Hauptthemen laut MEDLINE: Anthrax, Bacillus anthracis, Anti-Bacterial Agents, beta Lactam Antibiotics. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Defense Threat Reduction Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bacillus anthracis is a gram-positive, spore-forming bacterium and the etiological agent of anthrax. As a Tier 1 Select Agent, the pathogen can be isolated from the natural environment, and the endospore is a significant biological threat that can be produced in large quantities, stored, and disseminated by aerosolization. The intentional release of B. anthracis spores has the potential for mass casualties and is a serious threat to public and military health. Fluoroquinolones and tetracyclines are common antibiotics used for post-exposure prophylaxis and treatment in the United States (U.S.), whereas penicillin is the drug of choice throughout the rest of the world. However, these commonly used antibiotics may be contraindicated or suboptimal in a public health crisis. Thus, there is a need for novel medical countermeasures to be developed and tested against B. anthracis . Sulopenem is a broad-spectrum, orally bioavailable penem antibiotic recently approved in the U.S. for the treatment of uncomplicated urinary tract infections in women with limited therapeutic options. Here, we demonstrate that sulopenem has potent in vitro activity against both wild-type virulent B. anthracis strains, as well as biosafety level 2 surrogate strains resistant to current standards of care. Using human-equivalent dosing regimens, we show that sulopenem is highly protective in both the mouse and rabbit inhalational anthrax models. Together, these results support continued evaluation of this oral penem as a countermeasure for inhalational anthrax.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnthraxBacillus anthracisAnti-Bacterial Agentsbeta Lactam AntibioticsRespiratory Tract InfectionsAnimalsRabbitsMiceFemaleDisease Models, AnimalMicrobial Sensitivity Tests

Stichwörter der Autor:innen

Bacillus anthracisanthraxbiodefenseciprofloxacinsulopenem

Substanzen

Anti-Bacterial Agentsbeta Lactam Antibiotics

Autor:innen und Institutionen

  • Bacteriology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
  • Chenega Professional and Technical Service, Frederick, Maryland, USA.
  • Iterum Therapeutics, Old Saybrook, Connecticut, USA.

ORCID-Profile: Jennifer Chua, Steven I Aronin, Michael W Dunne, Christopher K Cote, J Matthew Meinig

Förderung

  • Defense Threat Reduction Agency

Zitieren

APA

Chua, J., Gray, A. M., Aronin, S. I., Puttagunta, S., Dunne, M. W., Halasohoris, S. A., Spencer, J. L., Babyak, A. L., Torres, M. E., Curry, B. J., Klimko, C. P., Cote, C. K., Hourihan, M. K., & Meinig, J. M. (2026). In vitro activity and in vivo efficacy of sulopenem against Bacillus anthracis in inhalational anthrax mouse and rabbit models. Antimicrobial Agents and Chemotherapy, 70(8). https://doi.org/10.1128/aac.00399-26

Vancouver

Chua J, Gray AM, Aronin SI, Puttagunta S, Dunne MW, Halasohoris SA, et al. In vitro activity and in vivo efficacy of sulopenem against Bacillus anthracis in inhalational anthrax mouse and rabbit models. Antimicrobial Agents and Chemotherapy. 2026;70(8). doi:10.1128/aac.00399-26

BibTeX
@article{Chua2026,
  author = {Chua, Jennifer and Gray, Annette M and Aronin, Steven I and Puttagunta, Sailaja and Dunne, Michael W and Halasohoris, Stephanie A and Spencer, Jade L and Babyak, Ashley L and Torres, Majorie E and Curry, Bobby J and Klimko, Christopher P and Cote, Christopher K and Hourihan, Mary K and Meinig, J Matthew},
  title = {In vitro activity and in vivo efficacy of sulopenem against Bacillus anthracis in inhalational anthrax mouse and rabbit models},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {8},
  doi = {10.1128/aac.00399-26}
}
Kostenlos starten →